Pitavastatin Compared with Differential Intervention Trial by Standard Therapy on Cardiovascular Events in Patients with Dyslipidemia on Chronic Hemodialysis (DIALYSIS): A Randomized Controlled Trial

Introduction: Statin has been reported to reduce cardiovascular events. However, the comparative efficacy of statin with standard therapy on cardiovascular events has not been sufficiently reported in patients on chronic hemodialysis. Thus, this study aimed to compare the effects of pitavastatin and standard therapy on mortality and cardiovascular events in chronic hemodialysis patients with dyslipidemia in Japan. Methods: Patients on chronic hemodialysis with dyslipidemia were randomized into pitavastatin-administered (pitavastatin group) or dietary therapy as standard therapy (control) group. Primary outcomes are all-cause mortality and myocardial infarction; secondary outcomes are cardiac arrest and fatal myocardial infarction. The composite outcomes included the incidence of coronary intervention, stroke, fracture, and hospitalization due to heart failure and unstable angina. The clinical outcome analyses used a logistic regression model to categorize the variables. A p value of <0.05 was considered statistically significant. Results: This study included 848 patients (422 in the control group and 426 in the pitavastatin group) from 79 health facilities. The mean age of the patients was 60.1±10.3 years, and the dialysis period was 7.2±7.6 years. The mean observation period was 36.5 months. The low-density lipoprotein cholesterol level was significantly lower than the baseline value in the pitavastatin group after 12 months of trial (79.8±26.1 vs. 107.8±25.5 mg/dL, p < 0.001). Moreover, the total number of deaths was 85, of which 50 occurred in the control group and 35 in the pitavastatin group. In an analysis adjusted for confounding factors due to participant attributes, there was a significant difference between the control group and the pitavastatin group in the primary and composite endpoints (p = 0.007 and p = 0.022, respectively). Conclusion: Our study has demonstrated that aggressive intervention with pitavastatin is more effective than the standard (dietary) therapy for improving the clinical outcomes in patients with dyslipidemia on chronic hemodialysis.

[1]  C. Kan,et al.  Post-Coronary Artery Bypass Medications in Dialysis Patients: Do We Need to Change Strategies? , 2019, The Thoracic and Cardiovascular Surgeon.

[2]  J. McMurray,et al.  Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence , 2019, Current Atherosclerosis Reports.

[3]  S. Hedayati,et al.  Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data? , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  L. Orlić,et al.  Dyslipidemia in patients with chronic kidney disease: etiology and management , 2017, International journal of nephrology and renovascular disease.

[5]  J. Fleg,et al.  Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. , 2016, Atherosclerosis.

[6]  C. Wanner,et al.  The heart and vascular system in dialysis , 2016, The Lancet.

[7]  Tzeng-Ji Chen,et al.  The beneficial effects of statins in patients undergoing hemodialysis. , 2013, International journal of cardiology.

[8]  J. Davignon.  Pleiotropic effects of pitavastatin , 2011, British journal of clinical pharmacology.

[9]  M. Chapman.  Pitavastatin: novel effects on lipid parameters. , 2011, Atherosclerosis. Supplements.

[10]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[11]  B. Zhang,et al.  Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[12]  J. Marrs,et al.  Effects of Lipid‐Lowering Therapy on Reduction of Cardiovascular Events in Patients with End‐Stage Renal Disease Requiring Hemodialysis , 2010, Pharmacotherapy.

[13]  M. Urashima,et al.  Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. , 2010, Journal of atherosclerosis and thrombosis.

[14]  N. Hounslow,et al.  Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. , 2010, Atherosclerosis.

[15]  K. Iseki,et al.  Higher Survival Rates of Chronic Hemodialysis Patients on Anti-Hypertensive Drugs , 2009, Nephron Clinical Practice.

[16]  J. Sasaki,et al.  A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance , 2008, Clinical therapeutics.

[17]  W. Kim,et al.  Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. , 2007, Clinical therapeutics.

[18]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[19]  R. Wolfe,et al.  Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2003, Journal of the American Society of Nephrology : JASN.

[20]  R. Karas,et al.  Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease , 2003, Annals of Internal Medicine.

[21]  K. Iseki,et al.  Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. , 2002, Kidney international.

[22]  T. Shoji,et al.  Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. , 1999, Kidney international. Supplement.

[23]  P. M. da Silva.  Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[24]  P. Degoulet,et al.  Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. , 1982, Nephron.